Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

This study has been withdrawn prior to enrollment.
(Low accrual)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00659399
First received: April 10, 2008
Last updated: March 16, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: November 2010
  Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)